Marianne F. L. van Den Broek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marianne F. L. van Den Broek has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ilke De Boeck
Laboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp
3 shared publications - Irina Spacova
Laboratory of Applied Microbiology and Biotechnology (LAMB), Department of Bioscience Engineering University of Antwerp Antwerp Belgium
3 shared publications - Sarah Lebeer
University of Antwerp
3 shared publications Alix Simons
YUN NV Niel Belgium
2 shared publications- Dominique Schols
Molecular, Structural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49, Box 1049, 3000 Leuven, Belgium
2 shared publications Eline Cauwenberghs
Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience Engineering University of Antwerp Antwerp Belgium
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-13
Potential transfer of orally administered probiotics to the upper respiratory tract in children with otitis media with effusion
The upper respiratory tract (URT) microbiome is increasingly recognised as a key determinant of airway health, yet the potential of probiotics to beneficially modulate these communities remains largely unexplored, despite the high burden of URT infections such as otitis media (OM). This randomised controlled trial investigated the migration of two model probiotic strains, Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12, to different URT niches in 37 children with otitis media with effusion (OME) treated daily with oral oil drops for one month. URT samples from the adenoids, and nasopharynx were analysed with species-specific qRT-PCR and 16S amplicon sequencing. L. rhamnosus GG-like bacteria were detected in 4/19 of treated patients compared to 0/18 in the control group. Probiotic treatment with oral oil droplets modestly increased the prevalence of L. rhamnosus GG-like bacteria in the nasopharynx and adenoids (from 0% to 16.67% and 15.79% respectively), and a slight positive association was observed with the abundance of Dolosigranulum pigrum (effect size = 0.13). Interestingly, other factors, such as maternal antibiotic use after birth, were associated with a notable higher abundance of Moraxella catarrhalis/nonliquefaciens (Maaslin effect size = 5.10), and a lower abundance of Streptococcus pneumoniae/pseudopneumoniae (Maaslin effect size = −2.27). In conclusion, this study suggests that oral probiotics might modulate the URT microbiome in ways relevant to OM, although the magnitude and direction of effects likely depend on the specific strains used. The trial was registered at ClinicalTrials.gov under B300201731908.
- 17 September 2026
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-13
Open AccessPotential transfer of orally administered probiotics to the upper respiratory tract in children with otitis media with effusion
The upper respiratory tract (URT) microbiome is increasingly recognised as a key determinant of airway health, yet the potential of probiotics to beneficially modulate these communities remains largely unexplored, despite the high burden of URT infections such as otitis media (OM). This randomised controlled trial investigated the migration of two model probiotic strains, Lacticaseibacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12, to different URT niches in 37 children with otitis media with effusion (OME) treated daily with oral oil drops for one month. URT samples from the adenoids, and nasopharynx were analysed with species-specific qRT-PCR and 16S amplicon sequencing. L. rhamnosus GG-like bacteria were detected in 4/19 of treated patients compared to 0/18 in the control group. Probiotic treatment with oral oil droplets modestly increased the prevalence of L. rhamnosus GG-like bacteria in the nasopharynx and adenoids (from 0% to 16.67% and 15.79% respectively), and a slight positive association was observed with the abundance of Dolosigranulum pigrum (effect size = 0.13). Interestingly, other factors, such as maternal antibiotic use after birth, were associated with a notable higher abundance of Moraxella catarrhalis/nonliquefaciens (Maaslin effect size = 5.10), and a lower abundance of Streptococcus pneumoniae/pseudopneumoniae (Maaslin effect size = −2.27). In conclusion, this study suggests that oral probiotics might modulate the URT microbiome in ways relevant to OM, although the magnitude and direction of effects likely depend on the specific strains used. The trial was registered at ClinicalTrials.gov under B300201731908.
- Open Access
- 5 December 2022
- Published by Wiley in Microbial Biotechnology
- Vol. 16 (1) , 99-115
Development of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections
Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut‐targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the formulation of a throat spray with live lactobacilli exhibiting several in vitro mechanisms of action against respiratory viral infections, including induction of interferon regulatory pathways and direct inhibition of respiratory viruses. Rational selection of Lactobacillaceae strains was based on previously documented beneficial properties, up‐scaling and industrial production characteristics, clinical safety parameters, and potential antiviral and immunostimulatory efficacy in the URT demonstrated in this study. Using a three‐step selection strategy, three strains were selected and further tested in vitro antiviral assays and in formulations: Lacticaseibacillus casei AMBR2 as a promising endogenous candidate URT probiotic with previously reported barrier‐enhancing and anti‐pathogenic properties and the two well‐studied model strains Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 that display immunomodulatory capacities. The three strains and their combination significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV‐229E coronavirus in co‐culture models with bacteria, virus, and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway‐inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form. Thus, the developed spray with live lactobacilli will be further explored in the clinic as a potential broad‐acting live biotherapeutic strategy against respiratory viral diseases.
- 5 December 2022
- Published by Wiley in Microbial Biotechnology
- Vol. 16 (1) , 99-115
Open AccessDevelopment of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections
Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut‐targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the formulation of a throat spray with live lactobacilli exhibiting several in vitro mechanisms of action against respiratory viral infections, including induction of interferon regulatory pathways and direct inhibition of respiratory viruses. Rational selection of Lactobacillaceae strains was based on previously documented beneficial properties, up‐scaling and industrial production characteristics, clinical safety parameters, and potential antiviral and immunostimulatory efficacy in the URT demonstrated in this study. Using a three‐step selection strategy, three strains were selected and further tested in vitro antiviral assays and in formulations: Lacticaseibacillus casei AMBR2 as a promising endogenous candidate URT probiotic with previously reported barrier‐enhancing and anti‐pathogenic properties and the two well‐studied model strains Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 that display immunomodulatory capacities. The three strains and their combination significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV‐229E coronavirus in co‐culture models with bacteria, virus, and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway‐inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form. Thus, the developed spray with live lactobacilli will be further explored in the clinic as a potential broad‐acting live biotherapeutic strategy against respiratory viral diseases.
- Open Access
Live biotherapeutic throat spray for respiratory virus inhibition and interferon pathway induction
Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut-targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the selection and formulation of a broad-acting throat spray with live lactobacilli which induce interferon regulatory pathways and are able to inhibit respiratory viruses. Rational selection of Lactobacillaceae strains was based on safety, applicability, and potential antiviral and immunostimulatory efficacy in the URT. Three strains, Lacticaseibacillus casei AMBR2, Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV-229E coronavirus in co-culture models with bacteria, virus and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway-inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form.
Open AccessLive biotherapeutic throat spray for respiratory virus inhibition and interferon pathway induction
Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut-targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the selection and formulation of a broad-acting throat spray with live lactobacilli which induce interferon regulatory pathways and are able to inhibit respiratory viruses. Rational selection of Lactobacillaceae strains was based on safety, applicability, and potential antiviral and immunostimulatory efficacy in the URT. Three strains, Lacticaseibacillus casei AMBR2, Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV-229E coronavirus in co-culture models with bacteria, virus and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway-inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form.